{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:31:55Z","timestamp":1787236315308,"version":"build-2736575974"},"reference-count":219,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Deanship of Scientific Research at Northern Border University","award":["NBU-FFR-2025-2934-14"],"award-info":[{"award-number":["NBU-FFR-2025-2934-14"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04848-8","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T04:49:14Z","timestamp":1764737354000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mechanisms of resistance to antibody-drug conjugates in cancer: molecular barriers and pharmacological solutions"],"prefix":"10.1007","volume":"95","author":[{"given":"Lina","family":"Eltaib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandana","family":"Maji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Malathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Sadique","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"key":"4848_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck A, Goetsch L, Dumontet C, Corva\u00efa N (2017) Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 16:315\u2013337","journal-title":"Nat Rev Drug Discov"},{"key":"4848_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00373","volume":"10","author":"H Tang","year":"2019","unstructured":"Tang H, Liu Y, Yu Z, Sun M, Lin L, Liu W et al (2019) The analysis of key factors related to ADCs structural design. Front Pharmacol 10:373","journal-title":"Front Pharmacol"},{"key":"4848_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25204764","author":"U Hafeez","year":"2020","unstructured":"Hafeez U, Parakh S, Gan HK, Scott AM (2020) Antibody-drug conjugates for cancer therapy. Molecules. https:\/\/doi.org\/10.3390\/molecules25204764","journal-title":"Molecules"},{"key":"4848_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02679-8","volume":"22","author":"HE Marei","year":"2022","unstructured":"Marei HE, Cenciarelli C, Hasan A (2022) Potential of antibody-drug conjugates (ADCs) for cancer therapy. Cancer Cell Int 22:255","journal-title":"Cancer Cell Int"},{"key":"4848_CR5","doi-asserted-by":"crossref","unstructured":"Jose J, Hooper JD, Souza-Fonseca-Guimaraes F (2025) Highlights of 2024. Broadening anti-cancer immunotherapy modalities with antibody-drug conjugates: emerging insights from clinical studies. Immunology and cell biology 103:530-4","DOI":"10.1111\/imcb.70017"},{"key":"4848_CR6","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","volume":"30","author":"J Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB et al (2024) Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med 30:2208\u20132215","journal-title":"Nat Med"},{"key":"4848_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMoa2206125","volume":"387","author":"SM Ansell","year":"2022","unstructured":"Ansell SM, Radford J, Connors JM, D\u0142ugosz-Danecka M, Kim WS, Gallamini A et al (2022) Overall survival with Brentuximab Vedotin in stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 387:310\u2013320","journal-title":"N Engl J Med"},{"key":"4848_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/1756287220980192","volume":"12","author":"M Alt","year":"2020","unstructured":"Alt M, Stecca C, Tobin S, Jiang DM, Sridhar SS (2020) Enfortumab vedotin in urothelial cancer. Ther Adv Urol 12:1756287220980192","journal-title":"Ther Adv Urol"},{"key":"4848_CR9","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M et al (2021) Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med 384:1529\u20131541","journal-title":"N Engl J Med"},{"key":"4848_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E et al (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9\u201320","journal-title":"N Engl J Med"},{"key":"4848_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ph16010037","author":"H Huang","year":"2022","unstructured":"Huang H, Huang F, Liang X, Fu Y, Cheng Z, Huang Y et al (2022) Afatinib reverses EMT via inhibiting CD44-Stat3 axis to promote radiosensitivity in nasopharyngeal carcinoma. Pharmaceuticals (Basel, Switzerland). https:\/\/doi.org\/10.3390\/ph16010037","journal-title":"Pharmaceuticals (Basel, Switzerland)"},{"key":"4848_CR12","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.2147\/JIR.S499403","volume":"18","author":"S Zhang","year":"2025","unstructured":"Zhang S, Chen W, Zhou J, Liang Q, Zhang Y, Su M et al (2025) The benefits and safety of monoclonal antibodies: implications for cancer immunotherapy. J Inflamm Res 18:4335\u20134357","journal-title":"J Inflamm Res"},{"key":"4848_CR13","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1093\/annonc\/mdw424","volume":"27","author":"AW Tolcher","year":"2016","unstructured":"Tolcher AW (2016) Antibody drug conjugates: lessons from 20 years of clinical experience. Ann Oncol 27:2168\u20132172","journal-title":"Ann Oncol"},{"key":"4848_CR14","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1158\/0008-5472.CAN-09-3546","volume":"70","author":"YV Kovtun","year":"2010","unstructured":"Kovtun YV, Audette CA, Mayo MF, Jones GE, Doherty H, Maloney EK et al (2010) Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res 70:2528\u20132537","journal-title":"Cancer Res"},{"issue":"18","key":"4848_CR15","doi-asserted-by":"publisher","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","volume":"25","author":"S Coats","year":"2019","unstructured":"Coats S, Williams M, Kebble B, Dixit R, Tseng L, Yao NS et al (2019) Antibody-drug conjugates: future directions in clinical and translational strategies to improve the therapeutic index. Clin Cancer Res 25(18):5441\u20135448","journal-title":"Clin Cancer Res"},{"key":"4848_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119674","author":"R Khoury","year":"2023","unstructured":"Khoury R, Saleh K, Khalife N, Saleh M, Chahine C, Ibrahim R et al (2023) Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms24119674","journal-title":"Int J Mol Sci"},{"key":"4848_CR17","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1021\/acsanm.4c06257","volume":"8","author":"R Zhang","year":"2025","unstructured":"Zhang R, Wang T, Shen H, Zhou X, Han Q, Li L et al (2025) Tumor microenvironment-responsive MnO x-mesoporous carbon nanoparticles for enhanced chemodynamic synergistic antitumor therapy. ACS Appl Nano Mater 8:2763\u20132773","journal-title":"ACS Appl Nano Mater"},{"key":"4848_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17060958","author":"I Buyukgolcigezli","year":"2025","unstructured":"Buyukgolcigezli I, Tenekeci AK, Sahin IH (2025) Opportunities and challenges in antibody-drug conjugates for cancer therapy: a new era for cancer treatment. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17060958","journal-title":"Cancers (Basel)"},{"key":"4848_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1615\/CritRevOncog.2024053419","volume":"29","author":"MK Gupta","year":"2024","unstructured":"Gupta MK, Gouda G, Vadde R (2024) Role of the tumor microenvironment in mediating resistance to anti-HER2 antibodies. Crit Rev Oncog 29:43\u201354","journal-title":"Crit Rev Oncog"},{"key":"4848_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102395","volume":"106","author":"E Nicol\u00f2","year":"2022","unstructured":"Nicol\u00f2 E, Giugliano F, Ascione L, Tarantino P, Corti C, Tolaney SM et al (2022) Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives. Cancer Treat Rev 106:102395","journal-title":"Cancer Treat Rev"},{"key":"4848_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2025.101322","volume":"15","author":"W You","year":"2025","unstructured":"You W, Zhou Z, Li Z, Yan J, Wang Y (2025) From foe to friend: rewiring oncogenic pathways through artificial Selenoprotein to combat immune-resistant tumor. J Pharm Anal 15:101322","journal-title":"J Pharm Anal"},{"key":"4848_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","volume":"21","author":"K Tsuchikama","year":"2024","unstructured":"Tsuchikama K, Anami Y, Ha SYY, Yamazaki CM (2024) Exploring the next generation of antibody-drug conjugates. Nat Rev Clin Oncol 21:203\u2013223","journal-title":"Nat Rev Clin Oncol"},{"key":"4848_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4161\/mabs.27022","volume":"6","author":"S Panowski","year":"2014","unstructured":"Panowski S, Bhakta S, Raab H, Polakis P, Junutula JR (2014) Site-specific antibody drug conjugates for cancer therapy. mAbs 6:34\u201345","journal-title":"mAbs"},{"key":"4848_CR24","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/14712598.2023.2276873","volume":"23","author":"T Fujii","year":"2023","unstructured":"Fujii T, Matsuda Y (2023) Novel formats of antibody conjugates: recent advances in payload diversity, conjugation, and linker chemistry. Expert Opin Biol Ther 23:1053\u20131065","journal-title":"Expert Opin Biol Ther"},{"key":"4848_CR25","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1021\/acs.bioconjchem.3c00374","volume":"34","author":"JM Sasso","year":"2023","unstructured":"Sasso JM, Tenchov R, Bird R, Iyer KA, Ralhan K, Rodriguez Y et al (2023) The evolving landscape of antibody-drug conjugates: in depth analysis of recent research progress. Bioconjug Chem 34:1951\u20132000","journal-title":"Bioconjug Chem"},{"key":"4848_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17040561","volume":"17","author":"J Lu","year":"2016","unstructured":"Lu J, Jiang F, Lu A, Zhang G (2016) Linkers having a crucial role in antibody-drug conjugates. Int J Mol Sci 17:561","journal-title":"Int J Mol Sci"},{"key":"4848_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2025.112758","volume":"209","author":"H Zeng","year":"2025","unstructured":"Zeng H, Zhang Y, Zhang M, Liu H, Liu J, Zhu L et al (2025) A signal enhanced lateral flow immunoassay based on core\u2013shell quantum dots labeled antibody and antigen for sensitive detection of CP4-EPSPS protein. Microchem J 209:112758","journal-title":"Microchem J"},{"key":"4848_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2174\/0115680096343056240828190900","volume":"25","author":"G Gupta","year":"2025","unstructured":"Gupta G, Hussain MS, Pant K, Ali H, Thapa R, Bhat AA (2025) Antibody-drug conjugates (ADCs): a novel therapy for Triple-Negative breast cancer (TNBC). Curr Cancer Drug Targets 25:108\u2013112","journal-title":"Curr Cancer Drug Targets"},{"key":"4848_CR29","first-page":"10","volume-title":"Importance and considerations of antibody engineering in antibody-Drug conjugates development from a clinical pharmacologist\u2019s perspective","author":"AT Lucas","year":"2021","unstructured":"Lucas AT, Moody A, Schorzman AN, Zamboni WC (2021) Importance and considerations of antibody engineering in antibody-Drug conjugates development from a clinical pharmacologist\u2019s perspective. Antibodies, Basel, Switzerland, p 10"},{"key":"4848_CR30","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/imm.13793","volume":"173","author":"ZB Wang","year":"2024","unstructured":"Wang ZB, Zhang X, Fang C, Liu XT, Liao QJ, Wu N et al (2024) Immunotherapy and the ovarian cancer microenvironment: exploring potential strategies for enhanced treatment efficacy. Immunology 173:14\u201332","journal-title":"Immunology"},{"key":"4848_CR31","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S (2021) Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol 18:327\u2013344","journal-title":"Nat Rev Clin Oncol"},{"key":"4848_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.8407","author":"X Jiang","year":"2024","unstructured":"Jiang X, Nik Nabil WN, Ze Y, Dai R, Xi Z, Xu H (2024) Unlocking natural potential: Antibody-drug conjugates with naturally derived payloads for cancer therapy. Phytother Res. https:\/\/doi.org\/10.1002\/ptr.8407","journal-title":"Phytother Res"},{"key":"4848_CR33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2174\/1574892816666210509001139","volume":"16","author":"V Edupuganti","year":"2021","unstructured":"Edupuganti V, Tyndall J, Gamble AB (2021) Self-immolative linkers in prodrugs and antibody drug conjugates in cancer treatment. Recent patents on anti-cancer drug discovery 16:479\u2013497","journal-title":"Recent patents on anti-cancer drug discovery"},{"key":"4848_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020396","author":"R Sheyi","year":"2022","unstructured":"Sheyi R, de la Torre BG, Albericio F (2022) Linkers: an assurance for controlled delivery of antibody-drug conjugate. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics14020396","journal-title":"Pharmaceutics"},{"key":"4848_CR35","doi-asserted-by":"publisher","first-page":"7782","DOI":"10.1021\/acs.chemrev.2c00915","volume":"123","author":"L Qian","year":"2023","unstructured":"Qian L, Lin X, Gao X, Khan RU, Liao JY, Du S et al (2023) The dawn of a new era: targeting the undruggables with antibody-based therapeutics. Chem Rev 123:7782\u20137853","journal-title":"Chem Rev"},{"key":"4848_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500262","volume":"20","author":"Y Lei","year":"2025","unstructured":"Lei Y, Zheng M, Chen P, Seng Ng C, Peng Loh T, Liu H (2025) Linker design for the antibody drug conjugates: a comprehensive review. ChemMedChem 20:e202500262","journal-title":"ChemMedChem"},{"key":"4848_CR37","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1021\/acs.bioconjchem.5c00037","volume":"36","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Cheng H, Jiang S, Tai W (2025) Fc multisite conjugation and prolonged delivery of the folate-targeted drug conjugate EC140. Bioconjug Chem 36:762\u2013769","journal-title":"Bioconjug Chem"},{"key":"4848_CR38","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/19420862.2016.1156829","volume":"8","author":"H Donaghy","year":"2016","unstructured":"Donaghy H (2016) Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates. mAbs 8:659\u2013671","journal-title":"mAbs"},{"key":"4848_CR39","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","volume":"24","author":"F Giugliano","year":"2022","unstructured":"Giugliano F, Corti C, Tarantino P, Michelini F, Curigliano G (2022) Bystander effect of antibody-drug conjugates: fact or fiction? Curr Oncol Rep 24:809\u2013817","journal-title":"Curr Oncol Rep"},{"key":"4848_CR40","doi-asserted-by":"crossref","unstructured":"Samantasinghar A, Sunildutt NP, Ahmed F, Soomro AM, Salih ARC, Parihar P et al (2023) A comprehensive review of key factors affecting the efficacy of antibody drug conjugate, vol 161. Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie, p 114408","DOI":"10.1016\/j.biopha.2023.114408"},{"key":"4848_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01035-z","volume":"14","author":"C Criscitiello","year":"2021","unstructured":"Criscitiello C, Morganti S, Curigliano G (2021) Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol 14:20","journal-title":"J Hematol Oncol"},{"key":"4848_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y (2022) Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Ther 7:93","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"4848_CR43","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.ymthe.2023.03.019","volume":"31","author":"Z Najminejad","year":"2023","unstructured":"Najminejad Z, Dehghani F, Mirzaei Y, Mer AH, Saghi SA, Abdolvahab MH et al (2023) Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer. Mol Ther 31(7):1874\u20131903","journal-title":"Mol Ther"},{"key":"4848_CR44","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.lungcan.2021.12.002","volume":"163","author":"A Desai","year":"2022","unstructured":"Desai A, Abdayem P, Adjei AA, Planchard D (2022) Antibody-drug conjugates: a promising novel therapeutic approach in lung cancer. Lung Cancer 163:96\u2013106","journal-title":"Lung Cancer"},{"key":"4848_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J (2020) Antibody-drug conjugates: a comprehensive review. Mol Cancer Res 18:3\u201319","journal-title":"Mol Cancer Res"},{"key":"4848_CR46","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","volume":"111","author":"MJ Birrer","year":"2019","unstructured":"Birrer MJ, Moore KN, Betella I, Bates RC (2019) Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst 111:538\u2013549","journal-title":"J Natl Cancer Inst"},{"key":"4848_CR47","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP (2017) Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer 117:1736\u20131742","journal-title":"Br J Cancer"},{"key":"4848_CR48","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A et al (2014) Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123:3128\u20133138","journal-title":"Blood"},{"key":"4848_CR49","doi-asserted-by":"crossref","unstructured":"Radocha J, van de Donk N, Weisel K (2021) Monoclonal antibodies and antibody drug conjugates in multiple myeloma. Cancers 13","DOI":"10.3390\/cancers13071571"},{"key":"4848_CR50","doi-asserted-by":"crossref","unstructured":"Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S et al (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398\u2013405","DOI":"10.1200\/JCO.2010.29.5865"},{"key":"4848_CR51","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1158\/1078-0432.CCR-17-0696","volume":"23","author":"M Sabbaghi","year":"2017","unstructured":"Sabbaghi M, Gil-G\u00f3mez G, Guardia C, Servitja S, Arp\u00ed O, Garc\u00eda-Alonso S et al (2017) Defective cyclin B1 induction in Trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer. Clin Cancer Res 23:7006\u20137019","journal-title":"Clin Cancer Res"},{"key":"4848_CR52","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1158\/1078-0432.CCR-19-1768","volume":"26","author":"R Chen","year":"2020","unstructured":"Chen R, Herrera AF, Hou J, Chen L, Wu J, Guo Y et al (2020) Inhibition of MDR1 overcomes resistance to Brentuximab vedotin in Hodgkin lymphoma. Clin Cancer Res 26:1034\u20131044","journal-title":"Clin Cancer Res"},{"key":"4848_CR53","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/sj.leu.2403350","volume":"18","author":"VH van der Velden","year":"2004","unstructured":"van der Velden VH, Boeckx N, Jedema I, te Marvelde JG, Hoogeveen PG, Boogaerts M et al (2004) High CD33-antigen loads in peripheral blood limit the efficacy of Gemtuzumab Ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 18:983\u2013988","journal-title":"Leukemia"},{"key":"4848_CR54","doi-asserted-by":"publisher","first-page":"15336","DOI":"10.1073\/pnas.1102855108","volume":"108","author":"T Aung","year":"2011","unstructured":"Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M et al (2011) Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci USA 108:15336\u201315341","journal-title":"Proc Natl Acad Sci USA"},{"key":"4848_CR55","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/jcp.22773","volume":"227","author":"V Ciravolo","year":"2012","unstructured":"Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M et al (2012) Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol 227:658\u2013667","journal-title":"J Cell Physiol"},{"key":"4848_CR56","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jnci\/djk134","volume":"99","author":"M Scaltriti","year":"2007","unstructured":"Scaltriti M, Rojo F, Oca\u00f1a A, Anido J, Guzman M, Cortes J et al (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628\u2013638","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"4848_CR57","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1158\/0008-5472.CAN-10-3795","volume":"71","author":"J Arribas","year":"2011","unstructured":"Arribas J, Baselga J, Pedersen K, Parra-Palau JL (2011) p95HER2 and breast cancer. Cancer Res 71(5):1515\u20131519","journal-title":"Cancer Res"},{"key":"4848_CR58","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1158\/1078-0432.CCR-16-0970","volume":"23","author":"MF Mercogliano","year":"2017","unstructured":"Mercogliano MF, De Martino M, Venturutti L, Rivas MA, Proietti CJ, Inurrigarro G et al (2017) TNF\u03b1-induced mucin 4 expression elicits trastuzumab resistance in HER2-positive breast cancer. Clin Cancer Res 23:636\u2013648","journal-title":"Clin Cancer Res"},{"key":"4848_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23793-7","volume":"12","author":"CM Yamazaki","year":"2021","unstructured":"Yamazaki CM, Yamaguchi A, Anami Y, Xiong W, Otani Y, Lee J et al (2021) Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat Commun 12:3528","journal-title":"Nat Commun"},{"key":"4848_CR60","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1158\/2159-8290.CD-20-1557","volume":"11","author":"OM Filho","year":"2021","unstructured":"Filho OM, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA et al (2021) Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discov 11:2474\u20132487","journal-title":"Cancer Discov"},{"key":"4848_CR61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain SM, Shastry M, Hamilton E (2023) Targeting HER2-positive breast cancer: advances and future directions. Nat Rev Drug Discov 22:101\u2013126","journal-title":"Nat Rev Drug Discov"},{"key":"4848_CR62","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nature14064","volume":"517","author":"HF Renard","year":"2015","unstructured":"Renard HF, Simunovic M, Lemi\u00e8re J, Boucrot E, Garcia-Castillo MD, Arumugam S et al (2015) Endophilin-A2 functions in membrane scission in clathrin-independent endocytosis. Nature 517:493\u2013496","journal-title":"Nature"},{"key":"4848_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0900-z","volume":"19","author":"T Baldassarre","year":"2017","unstructured":"Baldassarre T, Truesdell P, Craig AW (2017) Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers. Breast Cancer Res 19:110","journal-title":"Breast Cancer Res"},{"key":"4848_CR64","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semcdb.2014.03.034","volume":"31","author":"CC Scott","year":"2014","unstructured":"Scott CC, Vacca F, Gruenberg J (2014) Endosome maturation, transport and functions. Semin Cell Dev Biol 31:2\u201310","journal-title":"Semin Cell Dev Biol"},{"key":"4848_CR65","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1083\/jcb.112.1.55","volume":"112","author":"A Sorkin","year":"1991","unstructured":"Sorkin A, Krolenko S, Kudrjavtceva N, Lazebnik J, Teslenko L, Soderquist AM et al (1991) Recycling of epidermal growth factor-receptor complexes in A431 cells: identification of dual pathways. J Cell Biol 112:55\u201363","journal-title":"J Cell Biol"},{"key":"4848_CR66","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.yexcr.2008.07.029","volume":"315","author":"A Sorkin","year":"2009","unstructured":"Sorkin A, Goh LK (2009) Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 315:683\u2013696","journal-title":"Exp Cell Res"},{"key":"4848_CR67","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1091\/mbc.e03-08-0596","volume":"15","author":"AM Hommelgaard","year":"2004","unstructured":"Hommelgaard AM, Lerdrup M, van Deurs B (2004) Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 15:1557\u20131567","journal-title":"Mol Biol Cell"},{"key":"4848_CR68","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/0092-8674(90)90474-S","volume":"61","author":"S Felder","year":"1990","unstructured":"Felder S, Miller K, Moehren G, Ullrich A, Schlessinger J, Hopkins CR (1990) Kinase activity controls the sorting of the epidermal growth factor receptor within the multivesicular body. Cell 61:623\u2013634","journal-title":"Cell"},{"key":"4848_CR69","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1083\/jcb.200108152","volume":"155","author":"CE Futter","year":"2001","unstructured":"Futter CE, Collinson LM, Backer JM, Hopkins CR (2001) Human VPS34 is required for internal vesicle formation within multivesicular endosomes. J Cell Biol 155:1251\u20131264","journal-title":"J Cell Biol"},{"key":"4848_CR70","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.1091\/mbc.e04-07-0591","volume":"15","author":"CD Austin","year":"2004","unstructured":"Austin CD, De Mazi\u00e8re AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX et al (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15:5268\u20135282","journal-title":"Mol Biol Cell"},{"key":"4848_CR71","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1158\/1535-7163.MCT-06-0026","volume":"5","author":"LM Smith","year":"2006","unstructured":"Smith LM, Nesterova A, Alley SC, Torgov MY, Carter PJ (2006) Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin\/p97. Mol Cancer Ther 5:1474\u20131482","journal-title":"Mol Cancer Ther"},{"key":"4848_CR72","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","volume":"17","author":"M Sung","year":"2018","unstructured":"Sung M, Tan X, Lu B, Golas J, Hosselet C, Wang F et al (2018) Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1). Mol Cancer Ther 17:243\u2013253","journal-title":"Mol Cancer Ther"},{"key":"4848_CR73","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","volume":"10","author":"BT Li","year":"2020","unstructured":"Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y et al (2020) HER2-Mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov 10:674\u2013687","journal-title":"Cancer Discov"},{"key":"4848_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/antib9030049","author":"J Cheng","year":"2020","unstructured":"Cheng J, Liang M, Carvalho MF, Tigue N, Faggioni R, Roskos LK et al (2020) Molecular mechanism of HER2 rapid internalization and redirected trafficking induced by anti-HER2 biparatopic antibody. Antibodies. https:\/\/doi.org\/10.3390\/antib9030049","journal-title":"Antibodies"},{"key":"4848_CR75","doi-asserted-by":"publisher","DOI":"10.3390\/antib9030032","author":"JV Leyton","year":"2020","unstructured":"Leyton JV (2020) Improving receptor-mediated intracellular access and accumulation of antibody therapeutics-the tale of HER2. Antibodies. https:\/\/doi.org\/10.3390\/antib9030032","journal-title":"Antibodies"},{"key":"4848_CR76","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/cas.13253","volume":"108","author":"H Wang","year":"2017","unstructured":"Wang H, Wang W, Xu Y, Yang Y, Chen X, Quan H et al (2017) Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. Cancer Sci 108:1458\u20131468","journal-title":"Cancer Sci"},{"key":"4848_CR77","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","volume":"77","author":"C R\u00edos-Luci","year":"2017","unstructured":"R\u00edos-Luci C, Garc\u00eda-Alonso S, D\u00edaz-Rodr\u00edguez E, Nadal-Serrano M, Arribas J, Oca\u00f1a A et al (2017) Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity. Cancer Res 77:4639\u20134651","journal-title":"Cancer Res"},{"key":"4848_CR78","first-page":"31","volume":"2","author":"R Halaby","year":"2019","unstructured":"Halaby R (2019) Influence of lysosomal sequestration on multidrug resistance in cancer cells. Cancer Drug Resist (Alhambra Calif) 2:31\u201342","journal-title":"Cancer Drug Resist (Alhambra Calif)"},{"key":"4848_CR79","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3892\/ijo.2015.3066","volume":"47","author":"J Hrabeta","year":"2015","unstructured":"Hrabeta J, Groh T, Khalil MA, Poljakova J, Adam V, Kizek R et al (2015) Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells. Int J Oncol 47:971\u2013980","journal-title":"Int J Oncol"},{"key":"4848_CR80","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/0008-5472.CAN-15-1610","volume":"75","author":"KJ Hamblett","year":"2015","unstructured":"Hamblett KJ, Jacob AP, Gurgel JL, Tometsko ME, Rock BM, Patel SK et al (2015) SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm. Cancer Res 75:5329\u20135340","journal-title":"Cancer Res"},{"key":"4848_CR81","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1158\/1535-7163.MCT-17-0296","volume":"17","author":"G Li","year":"2018","unstructured":"Li G, Guo J, Shen BQ, Yadav DB, Sliwkowski MX, Crocker LM et al (2018) Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells. Mol Cancer Ther 17:1441\u20131453","journal-title":"Mol Cancer Ther"},{"key":"4848_CR82","doi-asserted-by":"publisher","first-page":"21141","DOI":"10.18632\/oncotarget.24975","volume":"9","author":"J Sauveur","year":"2018","unstructured":"Sauveur J, Matera EL, Chettab K, Valet P, Guitton J, Savina A et al (2018) Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway. Oncotarget 9:21141\u201321155","journal-title":"Oncotarget"},{"key":"4848_CR83","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1158\/1535-7163.MCT-10-0644","volume":"9","author":"M Lopus","year":"2010","unstructured":"Lopus M, Oroudjev E, Wilson L, Wilhelm S, Widdison W, Chari R et al (2010) Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules. Mol Cancer Ther 9:2689\u20132699","journal-title":"Mol Cancer Ther"},{"key":"4848_CR84","doi-asserted-by":"publisher","first-page":"7296","DOI":"10.1038\/sj.onc.1206935","volume":"22","author":"ZA Rasheed","year":"2003","unstructured":"Rasheed ZA, Rubin EH (2003) Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22:7296\u20137304","journal-title":"Oncogene"},{"key":"4848_CR85","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax2625","author":"F Coussy","year":"2020","unstructured":"Coussy F, El-Botty R, Ch\u00e2teau-Joubert S, Dahmani A, Montaudon E, Leboucher S et al (2020) BRCAness, SLFN11, and RB1 loss predict response to topoisomerase i inhibitors in triple-negative breast cancers. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aax2625","journal-title":"Sci Transl Med"},{"key":"4848_CR86","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/1535-7163.MCT-20-0351","volume":"20","author":"S Mao","year":"2021","unstructured":"Mao S, Chaerkady R, Yu W, D\u2019Angelo G, Garcia A, Chen H et al (2021) Resistance to pyrrolobenzodiazepine dimers is associated with SLFN11 downregulation and can be reversed through inhibition of ATR. Mol Cancer Ther 20:541\u2013552","journal-title":"Mol Cancer Ther"},{"key":"4848_CR87","first-page":"150","volume":"49","author":"M Cianfriglia","year":"2013","unstructured":"Cianfriglia M (2013) The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of Gemtuzumab Ozogamicin. Ann Ist Super Sanita 49:150\u2013168","journal-title":"Ann Ist Super Sanita"},{"key":"4848_CR88","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/1535-7163.MCT-15-0036","volume":"14","author":"R Chen","year":"2015","unstructured":"Chen R, Hou J, Newman E, Kim Y, Donohue C, Liu X et al (2015) CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther 14:1376\u20131384","journal-title":"Mol Cancer Ther"},{"key":"4848_CR89","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41580-023-00593-z","volume":"24","author":"AD McAinsh","year":"2023","unstructured":"McAinsh AD, Kops G (2023) Principles and dynamics of spindle assembly checkpoint signalling. Nat Rev Mol Cell Biol 24:543\u2013559","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4848_CR90","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1038\/s41388-017-0108-9","volume":"37","author":"\u00d6 Saatci","year":"2018","unstructured":"Saatci \u00d6, Borgoni S, Akbulut \u00d6, Durmu\u015f S, Raza U, Ey\u00fcpo\u011flu E et al (2018) Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2\/xL in HER2-positive breast cancer. Oncogene 37:2251\u20132269","journal-title":"Oncogene"},{"key":"4848_CR91","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11060-015-1900-4","volume":"125","author":"P Ramani","year":"2015","unstructured":"Ramani P, Nash R, Sowa-Avugrah E, Rogers C (2015) High levels of polo-like kinase 1 and phosphorylated translationally controlled tumor protein indicate poor prognosis in neuroblastomas. J Neurooncol 125:103\u2013111","journal-title":"J Neurooncol"},{"key":"4848_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129313","volume":"10","author":"TG Tut","year":"2015","unstructured":"Tut TG, Lim SH, Dissanayake IU, Descallar J, Chua W, Ng W et al (2015) Upregulated polo-like kinase 1 expression correlates with inferior survival outcomes in rectal cancer. PLoS One 10:e0129313","journal-title":"PLoS One"},{"key":"4848_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17697-1","volume":"11","author":"E Montaudon","year":"2020","unstructured":"Montaudon E, Nikitorowicz-Buniak J, Sourd L, Morisset L, El Botty R, Huguet L et al (2020) PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired Palbociclib resistance. Nat Commun 11:4053","journal-title":"Nat Commun"},{"key":"4848_CR94","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-01653-w","volume":"4","author":"M Dufies","year":"2021","unstructured":"Dufies M, Verbiest A, Cooley LS, Ndiaye PD, He X, Nottet N et al (2021) Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma. Commun Biol 4:166","journal-title":"Commun Biol"},{"key":"4848_CR95","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1158\/0008-5472.CAN-20-3580","volume":"81","author":"X Lu","year":"2021","unstructured":"Lu X, Pang Y, Cao H, Liu X, Tu L, Shen Y et al (2021) Integrated screens identify CDK1 as a therapeutic target in advanced gastrointestinal stromal tumors. Cancer Res 81:2481\u20132494","journal-title":"Cancer Res"},{"key":"4848_CR96","doi-asserted-by":"publisher","DOI":"10.1172\/JCI179570","author":"X Tian","year":"2024","unstructured":"Tian X, Srinivasan PR, Tajiknia V, Sanchez Sevilla Uruchurtu AF, Seyhan AA, Carneiro BA et al (2024) Targeting apoptotic pathways for cancer therapy. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI179570","journal-title":"J Clin Invest"},{"key":"4848_CR97","first-page":"2721","volume":"114","author":"D Dornan","year":"2009","unstructured":"Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K et al (2009) Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood 114:2721\u20132729","journal-title":"Blood"},{"key":"4848_CR98","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.1182\/blood-2003-11-3825","volume":"103","author":"RB Walter","year":"2004","unstructured":"Walter RB, Raden BW, Cronk MR, Bernstein ID, Appelbaum FR, Banker DE (2004) The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to Gemtuzumab ozogamicin. Blood 103:4276\u20134284","journal-title":"Blood"},{"key":"4848_CR99","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1158\/1535-7163.MCT-18-0743","volume":"18","author":"JJ Zoeller","year":"2019","unstructured":"Zoeller JJ, Vagodny A, Taneja K, Tan BY, O\u2019Brien N, Slamon DJ et al (2019) Neutralization of BCL-2\/X(L) enhances the cytotoxicity of T-DM1 in vivo. Mol Cancer Ther 18:1115\u20131126","journal-title":"Mol Cancer Ther"},{"key":"4848_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01374-8","volume":"22","author":"JJ Zoeller","year":"2020","unstructured":"Zoeller JJ, Vagodny A, Daniels VW, Taneja K, Tan BY, DeRose YS et al (2020) Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer. Breast Cancer Res 22:132","journal-title":"Breast Cancer Res"},{"key":"4848_CR101","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.exphem.2009.03.002","volume":"37","author":"P Haag","year":"2009","unstructured":"Haag P, Viktorsson K, Lindberg ML, Kanter L, Lewensohn R, Stenke L (2009) Deficient activation of bak and Bax confers resistance to Gemtuzumab ozogamicin-induced apoptotic cell death in AML. Exp Hematol 37:755\u2013766","journal-title":"Exp Hematol"},{"key":"4848_CR102","doi-asserted-by":"publisher","first-page":"5926","DOI":"10.1158\/1078-0432.CCR-11-1235","volume":"17","author":"X Du","year":"2011","unstructured":"Du X, Xiang L, Mackall C, Pastan I (2011) Killing of resistant cancer cells with low bak by a combination of an antimesothelin immunotoxin and a TRAIL receptor 2 agonist antibody. Clin Cancer Res 17:5926\u20135934","journal-title":"Clin Cancer Res"},{"key":"4848_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0782-4","volume":"17","author":"Z Du","year":"2018","unstructured":"Du Z, Lovly CM (2018) Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 17:58","journal-title":"Mol Cancer"},{"key":"4848_CR104","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.1073\/pnas.1016140108","volume":"108","author":"JT Garrett","year":"2011","unstructured":"Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, S\u00e1nchez V, Chakrabarty A et al (2011) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 108:5021\u20135026","journal-title":"Proc Natl Acad Sci USA"},{"key":"4848_CR105","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1158\/0008-5472.CAN-08-1056","volume":"69","author":"M Narayan","year":"2009","unstructured":"Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ (2009) Trastuzumab-induced HER reprogramming in resistant breast carcinoma cells. Cancer Res 69:2191\u20132194","journal-title":"Cancer Res"},{"key":"4848_CR106","doi-asserted-by":"publisher","first-page":"5486","DOI":"10.1158\/1078-0432.CCR-18-3191","volume":"24","author":"Correction","year":"2018","unstructured":"Correction (2018) Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-Positive metastatic breast cancer. Clin Cancer Research: Official J Am Association Cancer Res 24:5486","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"4848_CR107","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1002\/ijc.30276","volume":"139","author":"SB Kim","year":"2016","unstructured":"Kim SB, Wildiers H, Krop IE, Smitt M, Yu R, Lysbet de Haas S et al (2016) Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician\u2019s choice in previously treated HER2-positive advanced breast cancer. Int J Cancer 139:2336\u20132342","journal-title":"Int J Cancer"},{"key":"4848_CR108","doi-asserted-by":"publisher","DOI":"10.1142\/S1793545825300046","volume":"18","author":"X Men","year":"2025","unstructured":"Men X, Liu F, Gong M, Wang X, Wang L, Men X et al (2025) Activatable fluorescent probes for imaging and diagnosis of hepatocellular carcinoma. J Innov Opt Health Sci 18:2530004\u20132530025","journal-title":"J Innov Opt Health Sci"},{"key":"4848_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3224","volume":"14","author":"KL Mueller","year":"2012","unstructured":"Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K, Boerner JL (2012) Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res 14:R104","journal-title":"Breast Cancer Res"},{"key":"4848_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1065-8","volume":"15","author":"S Saito","year":"2015","unstructured":"Saito S, Morishima K, Ui T, Hoshino H, Matsubara D, Ishikawa S et al (2015) The role of HGF\/MET and FGF\/FGFR in fibroblast-derived growth stimulation and lapatinib-resistance of esophageal squamous cell carcinoma. BMC Cancer 15:82","journal-title":"BMC Cancer"},{"key":"4848_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1147-z","volume":"15","author":"M Liu","year":"2018","unstructured":"Liu M, Solomon W, Cespedes JC, Wilson NO, Ford B, Stiles JK (2018) Neuregulin-1 attenuates experimental cerebral malaria (ECM) pathogenesis by regulating ErbB4\/AKT\/STAT3 signaling. J Neuroinflammation 15:104","journal-title":"J Neuroinflammation"},{"key":"4848_CR112","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1158\/1078-0432.CCR-13-0358","volume":"20","author":"GD Phillips","year":"2014","unstructured":"Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K et al (2014) Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy. Clin Cancer Res 20:456\u2013468","journal-title":"Clin Cancer Res"},{"key":"4848_CR113","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","volume":"35","author":"EA Perez","year":"2017","unstructured":"Perez EA, Barrios C, Eiermann W, Toi M, Im YH, Conte P et al (2017) Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol 35:141\u2013148","journal-title":"J Clin Oncol"},{"key":"4848_CR114","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","volume":"19","author":"SA Hurvitz","year":"2018","unstructured":"Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM et al (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19:115\u2013126","journal-title":"Lancet Oncol"},{"key":"4848_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0464-1","volume":"7","author":"L D\u2019Amico","year":"2019","unstructured":"D\u2019Amico L, Menzel U, Prummer M, M\u00fcller P, Buchi M, Kashyap A et al (2019) A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer. J Immunother Cancer 7:16","journal-title":"J Immunother Cancer"},{"key":"4848_CR116","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1158\/2159-8290.CD-20-1434","volume":"11","author":"K Iida","year":"2021","unstructured":"Iida K, Abdelhamid Ahmed AH, Nagatsuma AK, Shibutani T, Yasuda S, Kitamura M et al (2021) Identification and therapeutic targeting of GPR20, selectively expressed in Gastrointestinal stromal tumors, with DS-6157a, a first-in-class antibody-drug conjugate. Cancer Discov 11:1508\u20131523","journal-title":"Cancer Discov"},{"key":"4848_CR117","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac4925","volume":"7","author":"P M\u00fcller","year":"2015","unstructured":"M\u00fcller P, Kreuzaler M, Khan T, Thommen DS, Martin K, Glatz K et al (2015) Trastuzumab emtansine (T-DM1) renders HER2\u2009+\u2009breast cancer highly susceptible to CTLA-4\/PD-1 blockade. Sci Transl Med 7:315ra188","journal-title":"Sci Transl Med"},{"issue":"7","key":"4848_CR118","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1158\/0008-5472.CAN-20-0434","volume":"81","author":"J Boshuizen","year":"2021","unstructured":"Boshuizen J, Pencheva N, Krijgsman O, Altimari DD, Castro PG, de Bruijn B et al (2021) Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade. Cancer Res 81(7):1775\u20131787","journal-title":"Cancer Res"},{"key":"4848_CR119","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","volume":"77","author":"J Rios-Doria","year":"2017","unstructured":"Rios-Doria J, Harper J, Rothstein R, Wetzel L, Chesebrough J, Marrero A et al (2017) Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies. Cancer Res 77:2686\u20132698","journal-title":"Cancer Res"},{"key":"4848_CR120","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1200\/JCO.2012.43.6832","volume":"31","author":"S Theurich","year":"2013","unstructured":"Theurich S, Malcher J, Wennhold K, Shimabukuro-Vornhagen A, Chemnitz J, Holtick U et al (2013) Brentuximab Vedotin combined with donor lymphocyte infusions for early relapse of hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncology: Official J Am Soc Clin Oncol 31:e59\u201363","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"key":"4848_CR121","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","volume":"15","author":"F Loganzo","year":"2016","unstructured":"Loganzo F, Sung M, Gerber HP (2016) Mechanisms of resistance to antibody-drug conjugates. Mol Cancer Ther 15:2825\u20132834","journal-title":"Mol Cancer Ther"},{"key":"4848_CR122","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1158\/1535-7163.MCT-14-0862","volume":"14","author":"F Loganzo","year":"2015","unstructured":"Loganzo F, Tan X, Sung M, Jin G, Myers JS, Melamud E et al (2015) Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther 14:952\u2013963","journal-title":"Mol Cancer Ther"},{"key":"4848_CR123","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1185\/03007995.2013.807232","volume":"29","author":"MA Sendur","year":"2013","unstructured":"Sendur MA, Aksoy S, Altundag K (2013) Cardiotoxicity of novel HER2-targeted therapies. Curr Med Res Opin 29:1015\u20131024","journal-title":"Curr Med Res Opin"},{"key":"4848_CR124","volume-title":"Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells","author":"ESW Ober","year":"2023","unstructured":"Ober ESW, Ober RJ, Kang JC-w, Sun W, Li R (2023) Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells. Google Patents, United States"},{"key":"4848_CR125","doi-asserted-by":"publisher","DOI":"10.3390\/antib12040072","author":"CH Song","year":"2023","unstructured":"Song CH, Jeong M, In H, Kim JH, Lin CW, Han KH (2023) Trends in the development of antibody-drug conjugates for cancer therapy. Antibodies Basel. https:\/\/doi.org\/10.3390\/antib12040072","journal-title":"Antibodies Basel"},{"key":"4848_CR126","doi-asserted-by":"publisher","DOI":"10.3390\/antib10040042","author":"MC Pettinato","year":"2021","unstructured":"Pettinato MC (2021) Introduction to antibody-drug conjugates. Antibodies (Basel). https:\/\/doi.org\/10.3390\/antib10040042","journal-title":"Antibodies (Basel)"},{"key":"4848_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/antib9010002","author":"D Leung","year":"2020","unstructured":"Leung D, Wurst JM, Liu T, Martinez RM, Datta-Mannan A, Feng Y (2020) Antibody conjugates-recent advances and future innovations. Antibodies. https:\/\/doi.org\/10.3390\/antib9010002","journal-title":"Antibodies"},{"key":"4848_CR128","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","volume":"9","author":"K Tsuchikama","year":"2018","unstructured":"Tsuchikama K, An Z (2018) Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell 9:33\u201346","journal-title":"Protein Cell"},{"key":"4848_CR129","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1039\/C7OB01027C","volume":"15","author":"Y Anami","year":"2017","unstructured":"Anami Y, Xiong W, Gui X, Deng M, Zhang CC, Zhang N et al (2017) Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency. Org Biomol Chem 15:5635\u20135642","journal-title":"Org Biomol Chem"},{"key":"4848_CR130","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2443538","volume":"17","author":"S Crescioli","year":"2025","unstructured":"Crescioli S, Kaplon H, Wang L, Visweswaraiah J, Kapoor V, Reichert JM (2025) Antibodies to watch in 2025. MAbs 17:2443538","journal-title":"MAbs"},{"key":"4848_CR131","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010154","author":"E D\u00edaz-Rodr\u00edguez","year":"2021","unstructured":"D\u00edaz-Rodr\u00edguez E, Gandullo-S\u00e1nchez L, Oca\u00f1a A, Pandiella A (2021) Novel ADCs and strategies to overcome resistance to anti-HER2 ADCs. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14010154","journal-title":"Cancers (Basel)"},{"key":"4848_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16040800","author":"BS Zimmerman","year":"2024","unstructured":"Zimmerman BS, Esteva FJ (2024) Next-generation HER2-targeted antibody-drug conjugates in breast cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers16040800","journal-title":"Cancers (Basel)"},{"key":"4848_CR133","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.drudis.2017.05.011","volume":"22","author":"S Sau","year":"2017","unstructured":"Sau S, Alsaab HO, Kashaw SK, Tatiparti K, Iyer AK (2017) Advances in antibody-drug conjugates: a new era of targeted cancer therapy. Drug Discov Today 22:1547\u20131556","journal-title":"Drug Discov Today"},{"key":"4848_CR134","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2174\/1567201816666191121145109","volume":"17","author":"N Amani","year":"2020","unstructured":"Amani N, Dorkoosh FA, Mobedi H (2020) ADCs, as novel revolutionary weapons for providing a step forward in targeted therapy of malignancies. Curr Drug Deliv 17:23\u201351","journal-title":"Curr Drug Deliv"},{"key":"4848_CR135","doi-asserted-by":"crossref","unstructured":"Dean Q, Luo S, Twomey D, Zhang B (2021) Targeting cancer with antibody-drug conjugates: promises and challenges. MAbs 13:1951427","DOI":"10.1080\/19420862.2021.1951427"},{"key":"4848_CR136","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/abt\/tbac001","volume":"5","author":"X Zhang","year":"2022","unstructured":"Zhang X, Huang AC, Chen F, Chen H, Li L, Kong N et al (2022) Novel development strategies and challenges for anti-Her2 antibody-drug conjugates. Antibody Therapeutics 5:18\u201329","journal-title":"Antibody Therapeutics"},{"key":"4848_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116522","volume":"174","author":"J Yu","year":"2024","unstructured":"Yu J, Li M, Liu X, Wu S, Li R, Jiang Y et al (2024) Implementation of antibody-drug conjugates in HER2-positive solid cancers: recent advances and future directions. Biomed Pharmacother 174:116522","journal-title":"Biomed Pharmacother"},{"key":"4848_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.847835","volume":"9","author":"J Yu","year":"2022","unstructured":"Yu J, Fang T, Yun C, Liu X, Cai X (2022) Antibody-drug conjugates targeting the human epidermal growth factor receptor family in cancers. Front Mol Biosci 9:847835","journal-title":"Front Mol Biosci"},{"key":"4848_CR139","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1080\/00498254.2020.1755909","volume":"50","author":"H Okamoto","year":"2020","unstructured":"Okamoto H, Oitate M, Hagihara K, Shiozawa H, Furuta Y, Ogitani Y et al (2020) Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. Xenobiotica 50:1242\u20131250","journal-title":"Xenobiotica"},{"key":"4848_CR140","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111682","volume":"183","author":"Z Xu","year":"2019","unstructured":"Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L et al (2019) Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab Deruxtecan(DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985). Eur J Med Chem 183:111682","journal-title":"Eur J Med Chem"},{"issue":"8","key":"4848_CR141","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/ijc.30870","volume":"141","author":"N Takegawa","year":"2017","unstructured":"Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y et al (2017) DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer 141(8):1682\u20131689","journal-title":"Int J Cancer"},{"key":"4848_CR142","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1080\/00498254.2018.1531158","volume":"49","author":"Y Nagai","year":"2019","unstructured":"Nagai Y, Oitate M, Shiozawa H, Ando O (2019) Comprehensive preclinical pharmacokinetic evaluations of trastuzumab Deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys. Xenobiotica 49:1086\u20131096","journal-title":"Xenobiotica"},{"key":"4848_CR143","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1248\/cpb.c18-00744","volume":"67","author":"T Nakada","year":"2019","unstructured":"Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T (2019) The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab Deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo) 67:173\u2013185","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"4848_CR144","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","volume":"20","author":"K Tamura","year":"2019","unstructured":"Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C et al (2019) Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol 20:816\u2013826","journal-title":"Lancet Oncol"},{"key":"4848_CR145","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094774","author":"A Indini","year":"2021","unstructured":"Indini A, Rijavec E, Grossi F (2021) Trastuzumab deruxtecan: changing the destiny of HER2 expressing solid tumors. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22094774","journal-title":"Int J Mol Sci"},{"key":"4848_CR146","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","volume":"22","author":"S Siena","year":"2021","unstructured":"Siena S, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H et al (2021) Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol 22:779\u2013789","journal-title":"Lancet Oncol"},{"key":"4848_CR147","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","volume":"25","author":"K Raghav","year":"2024","unstructured":"Raghav K, Siena S, Takashima A, Kato T, Van den Eynde M, Pietrantonio F et al (2024) Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol 25:1147\u20131162","journal-title":"Lancet Oncol"},{"key":"4848_CR148","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(24)00140-2","volume":"25","author":"BT Li","year":"2024","unstructured":"Li BT, Meric-Bernstam F, Bardia A, Naito Y, Siena S, Aftimos P et al (2024) Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study. Lancet Oncol 25:707\u2013719","journal-title":"Lancet Oncol"},{"key":"4848_CR149","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","volume":"10","author":"J Tsurutani","year":"2020","unstructured":"Tsurutani J, Iwata H, Krop I, J\u00e4nne PA, Doi T, Takahashi S et al (2020) Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov 10:688\u2013701","journal-title":"Cancer Discov"},{"key":"4848_CR150","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1470-2045(19)30088-9","volume":"20","author":"K Shitara","year":"2019","unstructured":"Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S et al (2019) Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol 20:827\u2013836","journal-title":"Lancet Oncol"},{"key":"4848_CR151","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s11523-023-00998-y","volume":"18","author":"C Kang","year":"2023","unstructured":"Kang C (2023) Trastuzumab deruxtecan: a review in gastric or gastro-oesophageal junction adenocarcinoma. Target Oncol 18:981\u2013989","journal-title":"Target Oncol"},{"key":"4848_CR152","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A (2023) Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov 22:641\u2013661","journal-title":"Nat Rev Drug Discov"},{"key":"4848_CR153","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.108106","volume":"236","author":"C Ceci","year":"2022","unstructured":"Ceci C, Lacal PM, Graziani G (2022) Antibody-drug conjugates: resurgent anticancer agents with multi-targeted therapeutic potential. Pharmacol Ther 236:108106","journal-title":"Pharmacol Ther"},{"key":"4848_CR154","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01397-y","volume":"16","author":"L Conilh","year":"2023","unstructured":"Conilh L, Sadilkova L, Viricel W, Dumontet C (2023) Payload diversification: a key step in the development of antibody-drug conjugates. J Hematol Oncol 16:3","journal-title":"J Hematol Oncol"},{"key":"4848_CR155","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116709","volume":"276","author":"M Xi","year":"2024","unstructured":"Xi M, Zhu J, Zhang F, Shen H, Chen J, Xiao Z et al (2024) Antibody-drug conjugates for targeted cancer therapy: recent advances in potential payloads. Eur J Med Chem 276:116709","journal-title":"Eur J Med Chem"},{"key":"4848_CR156","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30120743","volume":"30","author":"MA Fenton","year":"2023","unstructured":"Fenton MA, Tarantino P, Graff SL (2023) Sequencing antibody drug conjugates in breast cancer: exploring future roles. Curr Oncol 30:10211\u201310223","journal-title":"Curr Oncol"},{"key":"4848_CR157","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01362-9","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu Q, Qian W, Sun X, Jiang S (2022) Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol 15:143","journal-title":"J Hematol Oncol"},{"key":"4848_CR158","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107917","volume":"229","author":"Y Jin","year":"2022","unstructured":"Jin Y, Schladetsch MA, Huang X, Balunas MJ, Wiemer AJ (2022) Stepping forward in antibody-drug conjugate development. Pharmacol Ther 229:107917","journal-title":"Pharmacol Ther"},{"key":"4848_CR159","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202200032","volume":"17","author":"CSB Chia","year":"2022","unstructured":"Chia CSB (2022) A patent review on FDA-approved antibody-drug conjugates, their linkers and drug payloads. ChemMedChem 17:e202200032","journal-title":"ChemMedChem"},{"key":"4848_CR160","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26195847","author":"JTW Tong","year":"2021","unstructured":"Tong JTW, Harris PWR, Brimble MA, Kavianinia I (2021) An insight into FDA approved antibody-drug conjugates for cancer therapy. Molecules. https:\/\/doi.org\/10.3390\/molecules26195847","journal-title":"Molecules"},{"key":"4848_CR161","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01963-7","volume":"23","author":"K Liu","year":"2024","unstructured":"Liu K, Li M, Li Y, Li Y, Chen Z, Tang Y et al (2024) A review of the clinical efficacy of FDA-approved antibody\u2013drug conjugates in human cancers. Mol Cancer 23:62","journal-title":"Mol Cancer"},{"key":"4848_CR162","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21155510","author":"S Ponziani","year":"2020","unstructured":"Ponziani S, Di Vittorio G, Pitari G, Cimini AM, Ardini M, Gentile R et al (2020) Antibody-drug conjugates: the new frontier of chemotherapy. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21155510","journal-title":"Int J Mol Sci"},{"key":"4848_CR163","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP (2023) Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers15030713","journal-title":"Cancers (Basel)"},{"key":"4848_CR164","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11684-024-1072-8","volume":"18","author":"H Zeng","year":"2024","unstructured":"Zeng H, Ning W, Liu X, Luo W, Xia N (2024) Unlocking the potential of bispecific ADCs for targeted cancer therapy. Front Med 18:597\u2013621","journal-title":"Front Med"},{"key":"4848_CR165","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.23.00013","volume":"41","author":"A Passaro","year":"2023","unstructured":"Passaro A, J\u00e4nne PA, Peters S (2023) Antibody-drug conjugates in lung cancer: recent advances and implementing strategies. J Clin Oncol 41:3747\u20133761","journal-title":"J Clin Oncol"},{"key":"4848_CR166","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122676","volume":"347","author":"ZX Phuna","year":"2024","unstructured":"Phuna ZX, Kumar PA, Haroun E, Dutta D, Lim SH (2024) Antibody-drug conjugates: principles and opportunities. Life Sci 347:122676","journal-title":"Life Sci"},{"key":"4848_CR167","doi-asserted-by":"publisher","first-page":"6441","DOI":"10.1002\/jcp.26435","volume":"233","author":"H Nasiri","year":"2018","unstructured":"Nasiri H, Valedkarimi Z, Aghebati-Maleki L, Majidi J (2018) Antibody-drug conjugates: promising and efficient tools for targeted cancer therapy. J Cell Physiol 233:6441\u20136457","journal-title":"J Cell Physiol"},{"key":"4848_CR168","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1002\/cbic.201900178","volume":"20","author":"K Yamada","year":"2019","unstructured":"Yamada K, Ito Y (2019) Recent chemical approaches for site-specific conjugation of native antibodies: technologies toward next-generation antibody-drug conjugates. Chembiochem 20:2729\u20132737","journal-title":"Chembiochem"},{"key":"4848_CR169","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1007\/s11912-024-01582-x","volume":"26","author":"A Bhushan","year":"2024","unstructured":"Bhushan A, Misra P (2024) Economics of antibody drug conjugates (ADCs): innovation, investment and market dynamics. Curr Oncol Rep 26:1224\u20131235","journal-title":"Curr Oncol Rep"},{"key":"4848_CR170","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01459-y","volume":"23","author":"E Ferraro","year":"2021","unstructured":"Ferraro E, Drago JZ, Modi S (2021) Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions. Breast Cancer Res 23:84","journal-title":"Breast Cancer Res"},{"key":"4848_CR171","doi-asserted-by":"publisher","DOI":"10.3390\/genes13112065","author":"MK Najjar","year":"2022","unstructured":"Najjar MK, Manore SG, Regua AT, Lo HW (2022) Antibody-drug conjugates for the treatment of HER2-positive breast cancer. Genes. https:\/\/doi.org\/10.3390\/genes13112065","journal-title":"Genes"},{"key":"4848_CR172","doi-asserted-by":"publisher","DOI":"10.1172\/JCI172156","author":"HL Chang","year":"2023","unstructured":"Chang HL, Schwettmann B, McArthur HL, Chan IS (2023) Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI172156","journal-title":"J Clin Invest"},{"key":"4848_CR173","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041540","author":"Q Li","year":"2021","unstructured":"Li Q, Li W, Xu K, Xing Y, Shi H, Jing Z et al (2021) PEG linker improves antitumor efficacy and safety of Affibody-based drug conjugates. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22041540","journal-title":"Int J Mol Sci"},{"key":"4848_CR174","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J et al (2024) Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390:875\u2013888","journal-title":"N Engl J Med"},{"key":"4848_CR175","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241311011","author":"K Xu","year":"2023","unstructured":"Xu K, Han J, Yang L, Cao L, Li S, Hong Z (2023) Tumor site-specific cleavage improves the antitumor efficacy of antibody-drug conjugates. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms241311011","journal-title":"Int J Mol Sci"},{"key":"4848_CR176","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12282-020-01153-5","volume":"28","author":"S Yaghoubi","year":"2021","unstructured":"Yaghoubi S, Gharibi T, Karimi MH, Sadeqi Nezhad M, Seifalian A, Tavakkol R et al (2021) Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs). Breast Cancer 28:216\u2013225","journal-title":"Breast Cancer"},{"key":"4848_CR177","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/jcp.27085","volume":"234","author":"M Abdollahpour-Alitappeh","year":"2019","unstructured":"Abdollahpour-Alitappeh M, Lotfinia M, Bagheri N, Sineh Sepehr K, Habibi-Anbouhi M, Kobarfard F et al (2019) Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer. J Cell Physiol 234:2693\u20132704","journal-title":"J Cell Physiol"},{"key":"4848_CR178","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15164","volume":"9","author":"L Li","year":"2023","unstructured":"Li L, Cao J, Chen C, Qin Y, He L, Gu H et al (2023) Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer. Heliyon 9:e15164","journal-title":"Heliyon"},{"key":"4848_CR179","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo R, Tarantino P, Rich JR, LoRusso PM, de Vries EGE (2024) The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov 14:2089\u20132108","journal-title":"Cancer Discov"},{"key":"4848_CR180","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-017-0667-1","volume":"37","author":"C Chalouni","year":"2018","unstructured":"Chalouni C, Doll S (2018) Fate of antibody-drug conjugates in cancer cells. J Exp Clin Cancer Res 37:20","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"4848_CR181","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","volume":"43","author":"YF Chen","year":"2023","unstructured":"Chen YF, Xu YY, Shao ZM, Yu KD (2023) Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun 43(3):297\u2013337","journal-title":"Cancer Commun"},{"key":"4848_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102500","volume":"113","author":"C von Arx","year":"2023","unstructured":"von Arx C, De Placido P, Caltavituro A, Di Rienzo R, Buonaiuto R, De Laurentiis M et al (2023) The evolving therapeutic landscape of trastuzumab-drug conjugates: future perspectives beyond HER2-positive breast cancer. Cancer Treat Rev 113:102500","journal-title":"Cancer Treat Rev"},{"key":"4848_CR183","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60:1421\u20131434","journal-title":"Adv Drug Deliv Rev"},{"key":"4848_CR184","volume-title":"Goliath: the Structure, Function, and clinical prospects of antibody fragments","author":"A Bates","year":"2019","unstructured":"Bates A, Power CA (2019) David vs. Goliath: the Structure, Function, and clinical prospects of antibody fragments, vol 8. Antibodies, Basel, Switzerland"},{"key":"4848_CR185","doi-asserted-by":"crossref","unstructured":"Hopp J, Hornig N, Zettlitz KA, Schwarz A, Fuss N, M\u00fcller D et al (2010) The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Design & Selection: PEDS 23:827\u2009\u2013\u200934","DOI":"10.1093\/protein\/gzq058"},{"key":"4848_CR186","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay1359","author":"MS Kariolis","year":"2020","unstructured":"Kariolis MS, Wells RC, Getz JA, Kwan W, Mahon CS, Tong R et al (2020) Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aay1359","journal-title":"Sci Transl Med"},{"key":"4848_CR187","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","volume":"81","author":"J Niewoehner","year":"2014","unstructured":"Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P et al (2014) Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81:49\u201360","journal-title":"Neuron"},{"key":"4848_CR188","doi-asserted-by":"publisher","DOI":"10.3389\/fddev.2023.1227816","author":"WM Pardridge","year":"2023","unstructured":"Pardridge WM (2023) Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier. Frontiers in Drug Delivery. https:\/\/doi.org\/10.3389\/fddev.2023.1227816","journal-title":"Frontiers in Drug Delivery"},{"key":"4848_CR189","doi-asserted-by":"crossref","unstructured":"Croitoru A, Orr AA, MacKerell ADJr (2025) Harnessing computational technologies to facilitate antibody-drug conjugate development. Nat Chem Biol 21:1138\u20131147","DOI":"10.1038\/s41589-025-01950-z"},{"key":"4848_CR190","doi-asserted-by":"crossref","unstructured":"Kavousipour S, Barazesh M, Mohammadi S (2025) Artificial intelligence in antibody design and development: Harnessing the power of computational approaches. Med Bio Eng Comput","DOI":"10.1007\/s11517-025-03429-4"},{"key":"4848_CR191","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1124\/jpet.119.262287","volume":"374","author":"AP Singh","year":"2020","unstructured":"Singh AP, Seigel GM, Guo L, Verma A, Wong GG, Cheng HP et al (2020) Evolution of the systems pharmacokinetics-pharmacodynamics model for antibody-drug conjugates to characterize tumor heterogeneity and in vivo bystander effect. J Pharmacol Exp Ther 374:184\u2013199","journal-title":"J Pharmacol Exp Ther"},{"key":"4848_CR192","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1553853","volume":"16","author":"DE Zhang","year":"2025","unstructured":"Zhang DE, He T, Shi T, Huang K, Peng A (2025) Trends in the research and development of peptide drug conjugates: artificial intelligence aided design. Front Pharmacol 16:1553853","journal-title":"Front Pharmacol"},{"key":"4848_CR193","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.csbj.2024.12.030","volume":"27","author":"Y Wu","year":"2025","unstructured":"Wu Y, Xie L (2025) AI-driven multi-omics integration for multi-scale predictive modeling of genotype-environment-phenotype relationships. Comput Struct Biotechnol J 27:265\u2013277","journal-title":"Comput Struct Biotechnol J"},{"key":"4848_CR194","doi-asserted-by":"publisher","first-page":"10606","DOI":"10.1021\/acs.jmedchem.1c00895","volume":"64","author":"G Dong","year":"2021","unstructured":"Dong G, Ding Y, He S, Sheng C (2021) Molecular glues for targeted protein degradation: from serendipity to rational discovery. J Med Chem 64:10606\u201310620","journal-title":"J Med Chem"},{"key":"4848_CR195","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","volume":"184","author":"SL Schreiber","year":"2021","unstructured":"Schreiber SL (2021) The rise of molecular glues. Cell 184:3\u20139","journal-title":"Cell"},{"key":"4848_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104010","volume":"29","author":"MJ Nutt","year":"2024","unstructured":"Nutt MJ, Stewart SG (2024) Strengthening molecular glues: design strategies for improving thalidomide analogs as cereblon effectors and anticancer agents. Drug Discov Today 29:104010","journal-title":"Drug Discov Today"},{"key":"4848_CR197","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.tips.2025.04.002","volume":"46","author":"Y Tao","year":"2025","unstructured":"Tao Y, Lu Y, Yu B, Wang Y (2025) Molecular glue meets antibody: next-generation antibody-drug conjugates. Trends Pharmacol Sci 46:520\u2013534","journal-title":"Trends Pharmacol Sci"},{"key":"4848_CR198","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00783","volume":"68","author":"B Cheng","year":"2025","unstructured":"Cheng B, Wang Y, Hong Y, Zhou Y, Chen J, Zeng C (2025) Research progress in targeting GSPT1: molecular glues, bifunctional degraders, and antibody-enabled molecular glues for cancer therapy. J Med Chem 68:13169\u201313185","journal-title":"J Med Chem"},{"key":"4848_CR199","first-page":"108557","volume":"35","author":"L Guo","year":"2024","unstructured":"Guo L, Ding J, Zhou WJCCL (2024) Harnessing bacteria for tumor therapy. Curr Adv Challenges 35:108557","journal-title":"Curr Adv Challenges"},{"key":"4848_CR200","first-page":"165","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM et al (2022) Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin 72:165\u2013182","journal-title":"CA Cancer J Clin"},{"key":"4848_CR201","doi-asserted-by":"publisher","DOI":"10.1177\/17562872241249073","volume":"16","author":"C Domb","year":"2024","unstructured":"Domb C, Garcia JA, Barata PC, Mendiratta P, Rao S, Brown JR (2024) Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer. Ther Adv Urol 16:17562872241249073","journal-title":"Ther Adv Urol"},{"key":"4848_CR202","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.urolonc.2023.06.006","volume":"41","author":"J Thomas","year":"2023","unstructured":"Thomas J, Sun M, Getz T, Ho B, Nauseef JT, Tagawa ST (2023) Antibody-drug conjugates for urothelial carcinoma. Urol Oncol 41:420\u2013428","journal-title":"Urol Oncol"},{"key":"4848_CR203","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0879-y","volume":"22","author":"M Sarfaty","year":"2020","unstructured":"Sarfaty M, Rosenberg JE (2020) Antibody-drug conjugates in urothelial carcinomas. Curr Oncol Rep 22:13","journal-title":"Curr Oncol Rep"},{"key":"4848_CR204","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1039\/D2CS00141A","volume":"51","author":"PS Dragovich","year":"2022","unstructured":"Dragovich PS (2022) Degrader-antibody conjugates. Chem Soc Rev 51:3886\u20133897","journal-title":"Chem Soc Rev"},{"key":"4848_CR205","doi-asserted-by":"publisher","first-page":"15996","DOI":"10.1021\/acs.jmedchem.4c01289","volume":"67","author":"YB Poudel","year":"2024","unstructured":"Poudel YB, Thakore RR, Chekler EP (2024) The new frontier: merging molecular glue degrader and antibody-drug conjugate modalities to overcome strategic challenges. J Med Chem 67:15996\u201316001","journal-title":"J Med Chem"},{"key":"4848_CR206","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/17425247.2019.1645118","volume":"16","author":"E Merkul","year":"2019","unstructured":"Merkul E, Sijbrandi NJ, Muns JA, Aydin I, Adamzek K, Houthoff HJ et al (2019) First platinum(II)-based metal-organic linker technology (Lx\u00ae) for a plug-and-play development of antibody-drug conjugates (ADCs). Expert Opin Drug Deliv 16:783\u2013793","journal-title":"Expert Opin Drug Deliv"},{"key":"4848_CR207","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1158\/0008-5472.CAN-16-1900","volume":"77","author":"NJ Sijbrandi","year":"2017","unstructured":"Sijbrandi NJ, Merkul E, Muns JA, Waalboer DC, Adamzek K, Bolijn M et al (2017) A novel Platinum(II)-based bifunctional ADC linker benchmarked using 89Zr-Desferal and auristatin F-conjugated trastuzumab. Cancer Res 77:257\u2013267","journal-title":"Cancer Res"},{"key":"4848_CR208","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1021\/acs.molpharmaceut.5b00432","volume":"12","author":"CR Behrens","year":"2015","unstructured":"Behrens CR, Ha EH, Chinn LL, Bowers S, Probst G, Fitch-Bruhns M et al (2015) Antibody-drug conjugates (ADCs) derived from interchain cysteine cross-linking demonstrate improved homogeneity and other pharmacological properties over conventional heterogeneous ADCs. Mol Pharm 12:3986\u20133998","journal-title":"Mol Pharm"},{"key":"4848_CR209","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1021\/bc500189z","volume":"25","author":"PM Drake","year":"2014","unstructured":"Drake PM, Albers AE, Baker J, Banas S, Barfield RM, Bhat AS et al (2014) Aldehyde tag coupled with HIPS chemistry enables the production of ADCs conjugated site-specifically to different antibody regions with distinct in vivo efficacy and PK outcomes. Bioconjug Chem 25:1331\u20131341","journal-title":"Bioconjug Chem"},{"key":"4848_CR210","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejmech.2014.08.062","volume":"88","author":"AE Albers","year":"2014","unstructured":"Albers AE, Garofalo AW, Drake PM, Kudirka R, de Hart GW, Barfield RM et al (2014) Exploring the effects of linker composition on site-specifically modified antibody-drug conjugates. Eur J Med Chem 88:3\u20139","journal-title":"Eur J Med Chem"},{"key":"4848_CR211","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","volume":"129","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Liu K, Wang K, Zhu H (2023) Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer 129:283\u2013295","journal-title":"Cancer"},{"key":"4848_CR212","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101795","volume":"55","author":"Z Fu","year":"2023","unstructured":"Fu Z, Liu J, Li S, Shi C, Zhang Y (2023) Treatment-related adverse events associated with HER2-targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. EClinicalMedicine 55:101795","journal-title":"EClinicalMedicine"},{"key":"4848_CR213","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","volume":"20","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM (2023) Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol 20:558\u2013576","journal-title":"Nat Rev Clin Oncol"},{"key":"4848_CR214","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","volume":"36","author":"JC Masters","year":"2018","unstructured":"Masters JC, Nickens DJ, Xuan D, Shazer RL, Amantea M (2018) Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest New Drugs 36:121\u2013135","journal-title":"Invest New Drugs"},{"key":"4848_CR215","unstructured":"Lewis Phillips GJWAS (2011) Mechanisms of acquired resistance to trastuzumab emtansine (T-DM1). Presented at: World ADC Summit 2011. San Francisco, CA"},{"key":"4848_CR216","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1158\/1538-7445.AM2016-2113","volume":"76","author":"MS Sung","year":"2016","unstructured":"Sung MS, Tan X, Hosselet C, Cinque M, Upeslacis E, Golas J et al (2016) Caveolae-mediated endocytosis as a novel mechanism of resistance to T-DM1 ADC. Cancer Res 76:2113","journal-title":"Cancer Res"},{"key":"4848_CR217","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-14-2035","volume":"21","author":"SF Yu","year":"2015","unstructured":"Yu SF, Zheng B, Go M, Lau J, Spencer S, Raab H et al (2015) A novel anti-CD22 anthracycline-based antibody-drug conjugate (ADC) that overcomes resistance to auristatin-based ADCs. Clin Cancer Res 21:3298\u20133306","journal-title":"Clin Cancer Res"},{"key":"4848_CR218","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1158\/1538-7445.AM2014-688","volume":"74","author":"TS Lewis","year":"2014","unstructured":"Lewis TS, Gordon K, Li F, Weimann A, Bruders R, Miyamoto J et al (2014) Characterization and circumvention of drug resistance mechanisms in SGN-35-resistant HL and ALCL clonal cell lines. Cancer Res 74:688","journal-title":"Cancer Res"},{"key":"4848_CR219","first-page":"7634","volume":"50","author":"JJ Starling","year":"1990","unstructured":"Starling JJ, Maciak RS, Hinson NA, Hoskins J, Laguzza BC, Gadski RA et al (1990) In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates. Cancer Res 50:7634\u20137640","journal-title":"Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04848-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04848-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04848-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T06:02:53Z","timestamp":1764741773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04848-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":219,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4848"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04848-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"20 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trials number"}},{"value":"During the preparation of this work, the author(s) used ChatGPT to correct the grammatical and typographical errors in the manuscript. All authors have approved the final version of the manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declaration of Generative AI and AI-assisted technologies in the writing process"}}],"article-number":"118"}}